Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.

abstract：:It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

journal_title：Anti-cancer drugs

authors： Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

更新日期：1996-05-01 00:00:00

abstract：:The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

journal_title：Anti-cancer drugs

authors： Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

更新日期：1991-04-01 00:00:00

abstract：:Our study was to examine the roles of crizotinib and ceritinib in hepatocellular carcinoma (HCC) cells and explore the possible mechanisms. MTT assay was employed to examine the proliferation of five HCC cell lines treated with various concentrations of crizotinib or ceritinib. HepG2 and HCCLM3 cells were incubated wi...

journal_title：Anti-cancer drugs

authors： Yu Z,Zhao R

更新日期：2018-07-01 00:00:00

abstract：:The aim of this study was to evaluate the effect of coadministration of acid-reducing agents on the pharmacokinetic exposure of orally administered epidermal growth factor receptor inhibitor erlotinib, a drug that displays pH-dependent solubility. Two studies were conducted, the first with the proton pump inhibitor om...

journal_title：Anti-cancer drugs

authors： Kletzl H,Giraudon M,Ducray PS,Abt M,Hamilton M,Lum BL

更新日期：2015-06-01 00:00:00

abstract：:Salivary adenoid cystic carcinoma (SACC), which is one of the most common malignant tumors of the salivary glands, is associated with a poor long-term outcome. There are currently few therapeutic options for patients with SACC. Recent studies have shown the potential of the application of ultraviolet-C (UV-C) irradiat...

journal_title：Anti-cancer drugs

authors： Jiang Y,Ge XY,Liu SM,Zheng L,Huang MW,Shi Y,Fu J,Zhang JG,Li SL

更新日期：2014-10-01 00:00:00

abstract：:The ONYX-015 virus is a mutated adenovirus that in theory selectively replicates and induces cytolysis in tumor cells lacking functional p53. The present study investigated whether ONYX-015 viral infection alone or in combination with conventional chemotherapeutic agents could significantly increase apoptosis in human...

journal_title：Anti-cancer drugs

authors： Petit T,Davidson KK,Cerna C,Lawrence RA,Von Hoff DD,Heise C,Kirn D,Izbicka E

更新日期：2002-01-01 00:00:00

abstract：:Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not sup...

journal_title：Anti-cancer drugs

authors： Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

更新日期：2015-10-01 00:00:00

abstract：:In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculatur...

journal_title：Anti-cancer drugs

authors： Garde SV,Forté AJ,Ge M,Lepekhin EA,Panchal CJ,Rabbani SA,Wu JJ

更新日期：2007-11-01 00:00:00

abstract：:We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma concentrations of nevirapine (dose: 200 mg twice daily orally) and paclitaxel (dose: 100 mg/m(...

journal_title：Anti-cancer drugs

authors： Kappelhoff BS,Huitema AD,Mairuhu AT,Schellens JH,Beijnen JH

更新日期：2005-07-01 00:00:00

abstract：:Although 5-fluorouracil (5-FU) has been used to treat breast and colorectal cancers for several decades, bolus 5-FU has disappointing efficacy. Prolonged infusion schedules and biomodulation with leucovorin have resulted in improved response rates, but these have not translated into significant improvements in surviva...

journal_title：Anti-cancer drugs

authors： Johnston PG,Kaye S

更新日期：2001-09-01 00:00:00

abstract：:The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on...

journal_title：Anti-cancer drugs

authors： Caballero Romero Á,Delgado Ureña MT,Salmerón García A,Megías Fernández MT,Librada Porriño-Bustamante M,Cabeza Barrera J

更新日期：2018-10-01 00:00:00

abstract：:Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

journal_title：Anti-cancer drugs

authors： Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

更新日期：1997-10-01 00:00:00

abstract：:Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer. The synergism of these drugs has been demonstrated in vivo and in vitro. The aim of this study was to determine the recommended dose of the triple combination of L-OHP, CPT-11 and CI 5-FU for a...

journal_title：Anti-cancer drugs

authors： Abad A,Massutí B,Gallego J,Yuste AL,Manzano JL,Carrato A,Antón A,Marfa X,Diaz-Rubio E,Spanish Cooperative Group for Gastrointestinal Tumor Therapy.

更新日期：2004-06-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a water-soluble active metabolite of artemisinin derivatives, is the safest and most effective antimalarial analog of artemisinin. In the present investigation, we assessed the apoptotic effect of DHA on leukemia HL60 cells and its regulation of transferrin receptor (TfR). Cell growth inhibit...

journal_title：Anti-cancer drugs

authors： Zhou HJ,Wang Z,Li A

更新日期：2008-03-01 00:00:00

abstract：:The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a mechanism able to modify ErbB2 expression enhances the antitumor effect of trastuzumab. We analyzed whether granulocyte-colony stimulating factor (G-CSF), widely used...

journal_title：Anti-cancer drugs

authors： Cavalloni G,Sarotto I,Pignochino Y,Gammaitoni L,Migliardi G,Sgro L,Piacibello W,Risio M,Aglietta M,Leone F

更新日期：2008-08-01 00:00:00

abstract：:This review focuses on the recent advances in chemotherapy of malignant gliomas, with special emphasis on the most common primary brain tumor in adults, glioblastoma. The demonstration of the superiority of concomitant and adjuvant temozolomide with standard radiotherapy over radiotherapy alone in patients with newly ...

journal_title：Anti-cancer drugs

authors： Soffietti R,Rudà R,Trevisan E

更新日期：2007-07-01 00:00:00

abstract：:At the present time, there is not a standard regimen in upfront metastatic setting for breast cancer. A wide variety of regimens which includes anthracyclines, taxanes, gemcitabine or capecitabine are currently used, however, there is evidence to support the use of many of these drugs in early breast cancer and conseq...

journal_title：Anti-cancer drugs

authors： Estevez LG,Tusquets I,Muñoz M,Adrover E,Rovira PS,Seguí MA,Rodríguez CA,Lescure AR,Ruiz M,Alvarez I,Mata JG

更新日期：2007-08-01 00:00:00

abstract：:The role and regulation of the c-myc protooncogene in breast and ovarian neoplasms is receiving increased attention. The downregulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 (calcitriol), retinoic acid (RA) and dexamethasone (Dex) is closely associated with growth inhibition in leukemic cells. Calcitr...

journal_title：Anti-cancer drugs

authors： Saunders DE,Christensen C,Wappler NL,Schultz JF,Lawrence WD,Malviya VK,Malone JM,Deppe G

更新日期：1993-04-01 00:00:00

abstract：:Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

journal_title：Anti-cancer drugs

authors： Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

更新日期：2018-09-01 00:00:00

abstract：:Vinblastine at doses ranging from 0.2 to 6 mg/kg body weight was administered i.p. to mice in the absence or presence of the drugs PSC 833, cyclosporin A, mefloquine, quinidine and dipyridamole, all compounds that modulate the multidrug resistance pump and thus increase the accumulation of this cytotoxin in drug-resis...

journal_title：Anti-cancer drugs

authors： Lyubimov E,Lan LB,Pashinsky I,Stein WD

更新日期：1996-01-01 00:00:00

abstract：:There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

journal_title：Anti-cancer drugs

authors： Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

更新日期：2018-07-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial...

journal_title：Anti-cancer drugs

authors： West CM,Price P

更新日期：2004-03-01 00:00:00

abstract：:Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an inhibitor of Aurora-B, has recently emerged as a promising agent for cancer treatment. In this study, we aimed to investigate the effects of AZD1152-HQPA on reactive oxygen species (ROS) gene...

journal_title：Anti-cancer drugs

authors： Zekri A,Mesbahi Y,Ghanizadeh-Vesali S,Alimoghaddam K,Ghavamzadeh A,Ghaffari SH

更新日期：2017-09-01 00:00:00

abstract：:The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

journal_title：Anti-cancer drugs

authors： Medeiros KA,Joanitti GA,Silva LP

更新日期：2014-03-01 00:00:00

abstract：:Treatment of mammalian cells with chemotherapeutic drugs can result in perturbations of nucleotide pools. Monitoring these perturbations in cultured tumor cells from human sources is useful for assessment of the effect of drug therapy and a better understanding of the mechanism of action of these drugs. In this study,...

journal_title：Anti-cancer drugs

authors： Liu X,Zhang CC,Liu Z,Wei L,Liu YJ,Yu J,Sun LX

更新日期：2014-07-01 00:00:00

abstract：:Cantharidin is a natural toxin that possesses potent anti-tumor properties. Its clinical application, however, is limited due to severe side-effects. Its cytotoxicity is believed to be mediated by the inhibition of serine/threonine protein phosphatase 2A. In order to identify new compounds with potential clinical ther...

journal_title：Anti-cancer drugs

authors： Shan HB,Cai YC,Liu Y,Zeng WN,Chen HX,Fan BT,Liu XH,Xu ZL,Wang B,Xian LJ

更新日期：2006-09-01 00:00:00

abstract：:Irinotecan (CPT-11) is a camptothecin analog with low (about 10--20%) and variable oral bioavailability in animal models. Here, Caco-2 cells were used to evaluate the transepithelial transport of CPT-11 and its metabolites. Caco-2 cells demonstrated significant expression of P-glycoprotein (P-gp), multidrug resistance...

journal_title：Anti-cancer drugs

authors： Yamamoto W,Verweij J,de Bruijn P,de Jonge MJ,Takano H,Nishiyama M,Kurihara M,Sparreboom A

更新日期：2001-06-01 00:00:00

abstract：:Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

journal_title：Anti-cancer drugs

authors： Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

更新日期：2006-06-01 00:00:00

abstract：:The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

journal_title：Anti-cancer drugs

authors： Abe A,Yamada H

更新日期：2009-06-01 00:00:00

abstract：:Continuous exposure to daunorubicin (DNR) confers resistance against the drug-elicited lethality of leukemic cells and then reduces the remission rate. However, the detailed mechanisms involved in resistance development of leukemic cells to DNR remain unclear. Upregulation of aldo-keto reductases (AKRs) in human leuke...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Yamaguchi A,Morikawa Y,Kezuka C,Takazawa H,Endo S,El-Kabbani O,Tajima K,Ikari A,Hara A

更新日期：2014-09-01 00:00:00